The FDA issued tentative approval for Lantheus’ ANDA for PNT2003, an asserted generic equivalent to Novartis’ radioligand Lutathera (lutetium Lu 177 dotatate), even as Novartis pursues multiple patent infringement suits. The tentative approval recognizes bioequivalence but cannot convert to final approval while litigation over formulation and process patents proceeds. This regulatory move could pressure Lutathera’s pricing and supply if Lantheus ultimately clears legal hurdles, and it spotlights the unique IP complexity of radiopharmaceuticals, where formulation and process patents often protect marketed products. The case has drawn judicial commentary about its unusual scope and dispute density, highlighting litigation risk as a barrier to generic radiopharmaceutical entry.